Dynavax Technologies | DVAX - سود ناخالص در فروش



سود ناخالص در فروش تغییر دادن تاریخ
AbbVie USD 10.47B 605M 2025-09
Adma Biologics USD 88.82M 13.19M 2025-12
Agenus USD 34.2M 4.61M 2025-12
Amgen USD 6.48B 307M 2025-09
AstraZeneca USD 12.39B 5M 2025-12
Biogen USD 1.65B 34.6M 2025-12
BioMarin Pharmaceutical USD 713.01M 81.81M 2025-12
Bristol-Myers Squibb USD 8.79B 110M 2025-09
Gilead Sciences USD 6.31B 106M 2025-12
Glaxosmithkline GBP 8.75B 2.92B 2025-09
Merck USD 13.42B 431M 2025-09
Minerva Neurosciences -4.27M 26.79M 2024-12
Nektar Therapeutics USD 21.81M 8.06M 2025-12
Neurocrine Biosciences USD 787.9M 7M 2025-12
Novartis USD 10.25B 570M 2025-12
Pfizer USD 3.54B 7.61B 2025-09
Regeneron Pharmaceuticals USD 3.3B 67M 2025-12
Roche Holding CHF 22.09B 10.04B 2025-12
Sarepta Therapeutics USD 43.55M 204.36M 2025-12
TG Therapeutics USD 154.43M 20.81M 2025-12
Vertex Pharmaceuticals USD 2.72B 62.4M 2025-12